ENGAGE (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of binge eating disorder (BED) in adults.
Primary diagnosis of BED according to DSM-5 criteria.
Provides written informed consent to participate in the study before the conduct of any study procedures.
Male or female, aged 18 to 55 inclusive.
Prior exposure to solriamfetol/Sunosi, through either a clinical study or prescription.
Unable to comply with study procedures.
Medically inappropriate for study participation in the opinion of the investigator.
Axsome Therapeutics, Inc.
Lead sponsor